Triple antithrombotic therapy in cardiac patients: more questions than answers
Authors:
Open Access
- 2 December 2013
- journal article
- review article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 35 (4) , 216-223
Abstract
Many cardiac patients require combined antithrombotic therapy consisting of an anticoagulant and inhibition of platelet function. The most frequent indications are atrial fibrillation (AF) in combination with drug-eluting stent implantation and/or the presence of an acute coronary syndrome (ACS). Currently, the optimal combination of anticoagulants and anti-platelet therapy is unknown, but it is well established that the combination of regular doses and regimens as prescribed in AF or after ACS results in increased bleeding rates. In this review, we discuss the current literature and describe approaches to reduce the risk of bleeding hoping not to increase the rate of ischaemic events.Keywords
This publication has 52 references indexed in Scilit:
- A New Strategy for Discontinuation of Dual Antiplatelet TherapyJACC, 2012
- Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysisThe Lancet, 2012
- Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting StentsCirculation, 2012
- Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR)European Heart Journal, 2012
- Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)European Heart Journal, 2010
- Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)European Heart Journal, 2010
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2009
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm AssociationEP Europace, 2007
- Late Angiographic Stent Thrombosis (LAST) Events With Drug-Eluting StentsJACC, 2005